Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
13 août 2018 11h15 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical...
Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613 in Pancreatic Cancer and Other Gastrointestinal Malignancies
13 juil. 2018 09h15 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, July 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Eric Van Cutsem...
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
28 juin 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 28, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug...
Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
14 juin 2018 10h12 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways...
Rafael Pharmaceuticals to Present at 2018 BIO International Convention
04 juin 2018 14h33 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 04, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President & CEO of Rafael Pharmaceuticals, Inc., will present the company’s clinical development strategy as Rafael prepares for its...
Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
12 avr. 2018 11h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, April 12, 2018 (GLOBE NEWSWIRE) --
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I...
Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition
07 déc. 2017 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production...
Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer
16 nov. 2017 09h25 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation...
Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
08 sept. 2017 07h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BACKGROUND: Dr. Angela T. Alistar, Medical Director, GI Medical Oncology at Atlantic Health System Cancer Care, will lead a poster presentation at...
Rafael Pharmaceuticals to Present at 2017 BIO International Convention
19 juin 2017 14h30 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 19, 2017 (GLOBE NEWSWIRE) -- Sanjeev Luther, Chief Operating Officer of Rafael Pharmaceuticals, Inc. (formerly Cornerstone Pharmaceuticals, Inc.), will present the company’s...